Myelodysplastic Syndromes, Version 2.2015
Peter L. Greenberg(Stanford University), Courtney Smith, Lisa Kujawski, Amir T. Fathi(University of Southern California), Rami S. Komrokji(Moffitt Cancer Center), Olga Frankfurt, H. Joachim Deeg(Fred Hutch Cancer Center), Uma Borate(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Brady L. Stein(Barnes-Jewish Hospital), Daniel A. Pollyea(University of Colorado Denver), Amy E. DeZern(Johns Hopkins University), Virginia M. Klimek(Memorial Sloan Kettering Cancer Center), Lori J. Maness(Susan Thompson Buffett Foundation), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Clara D. Bloomfield(North Shore University Hospital), Rafael Bejar(UC San Diego Health System), John M. Bennett(University of Rochester Medical Center), Richard M. Stone(Dana-Farber Cancer Institute), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Dorothy A. Shead(University of the Witwatersrand), Paul J. Shami(University of Utah), Peter Westervelt(MACOM (United States)), Carlos M. de Castro(Barnes-Jewish Hospital), Margaret O’Donnell(City Of Hope National Medical Center), Benton M. Wheeler(University of Tennessee Health Science Center), Karin Gaensler(University of California, San Francisco), David Head
Cited by 54
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k